
JSP-3-RT + CAG
$70.00
Research blend of a triple incretin agonist and an amylin analog for multi-receptor metabolic studies.
- Purity
- >99%
- Testing
- 3rd-party
- Shipping
- Tracked, discreet
Want to know when it's available? Text us and we'll let you know.
Need the Certificate of Analysis for this batch? Request a COA.
About JSP-3-RT + CAG
Triple incretin and amylin receptor co-activation blend. Complementary metabolic axis research.
The JSP-3-RT + Cagrilintide Blend combines two mechanistically complementary peptides operating across distinct but convergent metabolic axes. JSP-3-RT is a triple GLP-1R/GIPR/GCGR co-agonist driving incretin-mediated insulin secretion, hepatic fat oxidation, and thermogenesis, while Cagrilintide is a long-acting acylated analog of human amylin that acts at amylin receptors (AMY1-3) and calcitonin receptors in the hypothalamus and brainstem to suppress glucagon secretion, slow gastric emptying, and modulate central satiety signaling. Because the incretin and amylin receptor systems engage appetite and energy homeostasis through largely non-overlapping central and peripheral pathways, their co-administration is studied as a model for multi-axis metabolic intervention — with particular interest in additive or synergistic effects on food intake suppression, body weight reduction, and glycemic stabilization that may exceed the efficacy of either compound alone.
Research applications
- GLP-1R/GIPR/GCGR and amylin receptor co-activation and non-overlapping satiety pathway research
- Central appetite suppression and hypothalamic/brainstem satiety signaling mechanism studies
- Glucagon suppression, gastric emptying modulation, and postprandial glycemic regulation research
- Additive and synergistic multi-axis body weight reduction and energy intake suppression studies
- Hepatic fat oxidation, thermogenesis, and cardiometabolic risk factor modulation pathway investigation



